1
|
Yamamoto H, Yamamura K, Nagasaki H, Suzuki T, Ninomiya F, Matsubara K, Harada N, Ohkubo S. Genome editing of Nf1, Pten, and Trp53 in neonatal mice induces glioblastomas positive for oligodendrocyte lineage transcription factor 2. J Toxicol Pathol 2021; 34:359-365. [PMID: 34629735 PMCID: PMC8484922 DOI: 10.1293/tox.2021-0029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 07/05/2021] [Indexed: 12/21/2022] Open
Abstract
To generate a mouse glioblastoma model by genome editing, we introduced Cas9 protein and
guide RNAs specific for Nf1, Pten, and
Trp53 into the neonatal mouse forebrain by electroporation. We found a
high incidence (approximately 90%) of glial tumor development, including glioblastomas, 15
weeks later. The histological features of the tumors were similar to those of diffuse
gliomas and, in some cases, similar to human glioblastomas, with microvascular
proliferation (glomeruloid structure). In addition, unlike glial fibrillary acidic protein
(GFAP)-positive glioblastomas generated using a similar method in a previous model, the
majority of tumor cells were positive for oligodendrocyte lineage transcription factor 2,
but negative for GFAP and neurofilaments. One base pair insertions identical to those seen
in a previous model were found around the target sequences in Nf1,
Pten, and Trp53, and additional deletions were found
only in Pten. Considering that the histological characteristics were
different from those seen in the previous model, our new model provides an additional
research tool to investigate the early stages of glioblastoma development.
Collapse
Affiliation(s)
- Hiromi Yamamoto
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| | - Keisuke Yamamura
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| | - Haruka Nagasaki
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| | - Takamasa Suzuki
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| | - Fumiko Ninomiya
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| | - Kenji Matsubara
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| | - Naomoto Harada
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| | - Shuichi Ohkubo
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki 300-2611, Japan
| |
Collapse
|